Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform

 Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform

Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform

Shots:

  • Dragonfly to receive ~ $47.5M up front, equity investment, development & commercial milestones along with royalties on sales of approved therapies
  • Merck to get an option to license exclusive IP rights for multiple candidates developed using Dragonfly’s TriNKET technology platform for new targets in oncology, infectious disease, and immune disorders
  • Dragonfly’s TriNKET technology act by harnessing the body’s innate immune system to bring breakthrough cancer therapies to the patients

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Dragonfly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post